PhaseBio Pharmaceuticals Gross Margin

Gross Margin of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Gross Margin growth rates and interactive chart. Gross profit margin shows the percentage of revenue that exceeds a company's costs of goods sold. It illustrates how well a company is generating revenue from the costs involved in producing their products and services. The higher the margin, the more effective the company's management is in generating revenue for each dollar of cost. Gross profit margin is calculated by subtracting the cost of goods sold from total revenue for the period and dividing that number by revenue. If a company has $200 million in revenue and $80 million in cost of goods sold, the gross margin is 60%.


Highlights and Quick Summary

  • Gross Margin for the quarter ending September 29, 2021 was 100.0% (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Gross Margin increased by Infinity%
  • Annual Gross Margin for 2020 was 100.0% (a -75.65% decrease from previous year)
  • Annual Gross Margin for 2019 was 410.61% (a -2712.02% decrease from previous year)
  • Annual Gross Margin for 2018 was -15.72% (a -Infinity% decrease from previous year)
  • Twelve month Gross Margin ending September 29, 2021 was 83.84% (a 3.29% increase compared to previous quarter)
  • Twelve month trailing Gross Margin increased by Infinity% year-over-year
Trailing Gross Margin for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
83.84% 81.17% 0.0% 0.0%
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Gross Margin of PhaseBio Pharmaceuticals

Most recent Gross Marginof PHAS including historical data for past 10 years.

Interactive Chart of Gross Margin of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Gross Margin for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 100.0% 100.0% 0.0%
2020 0.0% 0.0% 0.0% 100.0% 100.0%
2019 100.0% 100.0% 100.0% 100.0% 410.61%
2018 100.0% 100.0% -15.72%
2017 0.0%
2016 0.0%

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.